<DOC>
	<DOC>NCT01629732</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin</brief_summary>
	<brief_title>Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Males and females, ≥ 18 years of age Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4 HCV RNA viral load ≥ 10,000 IU/mL Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population) Body Mass Index (BMI) of 18 to 35 kg/m2 Seronegative for Hepatitis C virus (HIV) and Hepatitis B Evidence of decompensated liver disease Evidence of medical condition contributing to chronic liver disease other than HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>